Human Chorionic Gonadotropin hCG


Chorionic gonadotropin

Brand Names

Profasi® (mfg. Serono), Pregnyl® (mfg. Organon), Novarel® (mfg. Ferring), A.P.L.® (mfg. Wyeth-Ayerst)


Intramuscular injection


Demonstrated ovulatory dysfunction with:

  • Pre-treatment by human menotropins or follitropins
  • No evidence of primary ovarian failure
  • No prior allergic reaction to hCG

Used for

In women, inducing ovulation by stimulating the release of the egg from the follicle. In men, used to treat hypogonadism.

How does it work?

In women, behaves like luteinizing hormone (LH) to assist the corpus luteum in releasing progesterone, which is crucial to preparation of uterine lining for implantation. In men, stimulates Leydig (interstitial) cells of the testes to produce androgens (testosterone).

Suggested Evaluations


  • ovarian enlargement or cyst formation
  • uterine fibroid tumors
  • undiagnosed unusual vaginal bleeding
  • estrogen levels
  • primary pituitary or ovarian failure or enlargement
  • evidence of prostate cancer in men

During RX

  • mid-cycle urine LH test (OPK)
  • estrogen levels
  • mid-cycle ultrasound to detect follicle development

Usual Dosage

During a fertility treatment cycle, 5,000 to 10,000 USP units one day after last dose of menotropins or follitropins. For male treatment, 1,000 to 4,000 units two to three times weekly for several weeks.


Must be kept refrigerated. Maintain BBT chart or other recommended cycle charting methods throughout treatment cycle. Ovulation usually occurs approx. 36 hours after injection. Women with luteal phase defect may receive additional injections.

Common side effects

  • Injection site pain
  • Lower abdomen tenderness
  • Fluid retention
  • Headache
  • Emotional irritability
  • Breast discomfort
  • Fatigue
  • Multiple births

Side effects to report to your doctor

Severe pain or swelling in lower abdomen


  • May result in ovarian hyperstimulation.
  • May result in rupture of existing ovarian cysts.
  • May result in multiple births.
  • May result in arterial thromboembolism.
  • Can cause fluid retention, and thus should be used with caution in patients with cardiac or renal disease, epilepsy, migraine, or asthma.

Drug interactions or incompatibility

No known drug interactions.

Visitor Comments (0) - Be the first to comment
Adding your comments contributes to the adoption community. Please keep all comments on topic and civil. Visitors are invited to comment and vote for or flag comments based on appropriateness and helpfulness. All comments must adhere to our commenting rules and are subject to moderation.